SUCCESSFUL MANAGEMENT OF PERIPARTUM CARDIOMYOPATHY IN A YOUNG FEMALE PATIENT

Year 2021, Volume: 8 Issue: 3, 128 - 130, 01.10.2021

Ceren Yüksel Bengisu Çıray Mustafa Alperen Koşucu Servet Altay

Abstract

Aims: Peripartum cardiomyopathy is a rarely seen pregnancy-related myocardial disorder. The diagnosis is usually challenging and is made by exclusion. We aimed to present the recovery of a patient with peripartum cardiomyopathy as a result of a successful treatment plan. Case Report: A 26-year-old female patient with type-2 diabetes mellitus presented to the cardiology department of Trakya University School of Medicine. The patient experienced dyspnea and edema after delivery at 37 weeks of gestation. After the results of the blood tests, further cardiac examinations were deemed necessary. The echocardiogram revealed a low ejection fraction, indicating heart failure. The patient was recommended to halt breastfeeding and bromocriptine treatment was started. The patient was discharged one week later and kept under follow-up. Conclusion: Peripartum cardiomyopathy is a rare disease and therefore not easy to diagnose, but with appropriate treatment plans and frequent follow-ups, patients have high chances of full recovery.

Keywords

Peripartum, cardiomyopathy, pregnancy, bromocriptine, heart failure

References

• 1. Koenig T, Hilfiker-Kleiner D, Bauersachs J. Peripartum cardiomyopathy. Herz 2018;43(5):431-7.
• 2. Sliwa K, Hilfiker-Kleiner D, Petrie MC et al. Current state of knowledge on ae- tiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010;12(8):767-78.
• 3. Garg J, Palaniswamy C, Lanier GM. Peripartum cardiomyopathy: definition, inci- dence, etiopathogenesis, diagnosis, and management. Cardiol Rev 2015;23(2):69- 78.
• 4. Yamac H, Bultmann I, Sliwa K et al. Prolactin: a new therapeutic target in peripar- tum cardiomyopathy. Heart 2010;96(17):1352-7.
• 5. Abboud J, Murad Y, Chen-Scarabelli C et al. Peripartum cardiomyopathy: a com- prehensive review. Int J Cardiol 2007;118(3):295-303.
• 6. Baris L, Cornette J, Johnson MR et al. Peripartum cardiomyopathy: disease or syndrome? Heart 2019;105(5):357-62.
• 7. Ballo P, Betti I, Mangialavori G et al. Peripartum cardiomyopathy presenting with predominant left ventricular diastolic dysfunction: efficacy of bromocriptine. Case Rep Med 2012 Nov 22. doi: 10.1155/2012/476903. [Epub ahead of print]
• 8. Arrigo M, Blet A, Mebazaa A. Bromocriptine for the treatment of peripartum cardiomyopathy: welcome on BOARD. Eur Heart J 2017;38(35):2680-2.
• 9. Simon R, Yang S, Hameed AB. Bromocriptine use in peripartum cardiomyopathy: review of cases. AJP Rep 2018;8(4):e335-42.
• 10. Biteker M. Peripartum cardiomyopathy in Turkey. Int J Cardiol 2012;158(3):e60-1.
• 11. Elkayam U, Tummala PP, Rao K et al. Maternal and fetal outcomes of subse- quent pregnancies in women with peripartum cardiomyopathy. N Engl J Med 2001;344(21):1567-71.